Biology and genetics

Ex Vivo-expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients. Szmania S et al. J Immunother. 2014 Nov 20. [Epub ahead of print]. Establishment of a Murine Graft-versus-Myeloma Model Using Allogeneic Stem Cell Transplantation. Binsfeld M et al. PLoS One. 2014 Nov 21;9(11):e113764. doi: 10.1371/journal.pone.0113764. eCollection 2014. Exploration for the multi-effect of cardamom in’s resistance to multiple myeloma. Zhihua…

Details

Diagnostic tests and prognostic indicators

Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. Mathis S et al. Cytometry B Clin Cytom. 2014 Nov 17. doi: 10.1002/cyto.b.21200. [Epub ahead of print]. Clinical Course and Prognosis of Non-Secretory Multiple Myeloma. Chawla SS et al. Eur J Haematol. 2014 Nov 10. doi: 10.1111/ejh.12478. [Epub ahead of print]. The prognostic value…

Details

Related conditions

Plasma cell leukemia. Ravinet A et al. Bull Cancer. 2014 Nov 1;101(11):1048-1058. A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia. Kalff A et al. Haematologica. 2014 Nov 7. pii: haematol.2014.111385. [Epub ahead of print]. Solitary extramedullary plasmocytoma of the thyroid: a case report and histological approach to plasma cells infiltrate in the thyroid gland. Wilmars MM et…

Details

Emerging treatments

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Tolcher AW et al. Cancer Chemother Pharmacol. 2014 Nov 25. [Epub ahead of print]. Panobinostat: a review of trial results and future prospects in multiple myeloma. Libby EN et al. Expert Rev Hematol. 2014 Nov 20:1-10. [Epub ahead of print].…

Details

Supportive care

Treatment of multiple myeloma bone disease: experimental and clinical data. Papamerkouriou YM et al. Expert Opin Biol Ther. 2014 Nov 12:1-18. [Epub ahead of print]. Bisphosphonates in multiple myeloma: a fractured consensus. Kumar SK. Leuk Lymphoma. 2014 Nov 5:1-2. [Epub ahead of print]. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Berenson JR et al. Support Care…

Details

General

The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods. Kontodimopoulos N. Qual Life Res. 2014 Nov 13. [Epub ahead of print]. Prevalence of monoclonal gammopathy in HIV patients in 2014. Genet P et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19649. doi: 10.7448/IAS.17.4.19649. eCollection 2014.…

Details

Complications of myeloma and its treatments

Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. Sullivan MR et al. J Clin Apher. 2014 Nov 21. doi: 10.1002/jca.21371. [Epub ahead of print]. A case of endocapillary proliferative glomerulonephritis with macrophages phagocytosing monoclonal immunoglobulin lambda light chain. Watanabe H et al. Pathol Int. 2014 Nov 19. doi: 10.1111/pin.12229. [Epub ahead of print]. Successful re-administration of lenalidomide after lenalidomide-induced…

Details

Current treatments

Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma. Ong SY et al. Br J Haematol. 2014 Nov 21. doi: 10.1111/bjh.13238. [Epub ahead of print]. Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. Clark RE et al. Blood…

Details